Health ❯ Diabetes ❯ Type 2 Diabetes

Treatment Options

GLP-1 Receptor Agonists GLP-1 Agonists GLP-1 Medications Clinical Trials GLP-1 Drugs Medications Oral Medications Orforglipron GLP-1 Therapy Ozempic

Mounjaro Overtakes Keytruda as World’s Best-Selling Drug in Q1 2026

Soaring demand for GLP-1 therapies for metabolic disease is reshaping which medicines lead in sales.

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

Gurugram Bust Exposes Counterfeit Mounjaro Operation With Suspected China Link

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Brazil Cracks Down on Illicit Mounjaro Sales as Lilly Launches QR Verification Tool

Mounjaro Becomes India’s Top-Selling Drug by Value in October

Prue Leith Says Two-Month Mounjaro Trial Brought Side Effects but No Weight Loss

Lilly Taps Cipla to Market Tirzepatide as ‘Yurpeak’ in India at Mounjaro Price Parity

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

UK Mounjaro Orders Frozen Ahead of Price Hike as Korea Confronts Soaring Wegovy Use

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

FDA Approves Ozempic to Reduce Kidney Disease Risks in Type 2 Diabetes Patients

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy